Figure 2
Figure 2. Biodistribution of 131I-BC8 (anti-CD45) and 125I-BHV-1 (control) in a human T-NHL xenograft model. Biodistributions quantified as percentage injected radioiodine dose/g tissue (%ID/g) of 131I-BC8 (anti-CD45, ■) and 125I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

Biodistribution of 131I-BC8 (anti-CD45) and 125I-BHV-1 (control) in a human T-NHL xenograft model. Biodistributions quantified as percentage injected radioiodine dose/g tissue (%ID/g) of 131I-BC8 (anti-CD45, ■) and 125I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal